ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1302

Feasibility of Using Platelet PGDprime® Rapid Assay as a Peritonitis Screen for Peritoneal Dialysis Patients

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Shinefeld, Lisa A., Verax Biomedical Incorporated, Marlborough, Massachusetts, United States
  • Best, Nancy B., Verax Biomedical Incorporated, Marlborough, Massachusetts, United States
  • Vallejo, Remo P., Verax Biomedical Incorporated, Marlborough, Massachusetts, United States
Background

Peritoneal Dialysis (PD) patients carry the risk of bacterial infection via the catheter access site and the exit site. Peritonitis is suspected based on patient symptoms and the visual quality of effluent, but may not be confirmed until a sample of the effluent is tested at a central lab via culture. A result may take several days to generate. The Platelet PGDprime rapid test is a multiplexed immunoassay used to detect Gram-positive (GP) and Gram-negative (GN) bacteria in platelet units prior to transfusion. The utility of this rapid test for detection of bacteria in PD effluent was evaluated.

Methods

A sample (600 mL) of PD effluent from an asymptomatic patient was obtained and confirmed to be negative for bacteria by aerobic and anaerobic cell culture. Eight bacteria (5 GN & 3 GP) were grown in RPMI media and individually spiked at initially high levels into aliquots of the PD effluent, then serially diluted with the unspiked effluent in tenfold series. The CFU/mL of each starting spiking stock was quantified by OD at 620 nm. Each dilution was tested with PGDprime to determine the observed lowest detectable level of bacterial contamination by ten-fold dilution.

Results

The lowest detectable concentrations of bacteria are summarized in Table 1. The true Limit of Detection (LoD) for each species is between the lowest detectable concentration shown and the next lower logfold dilution level. Total test time was 25-35 minutes.

Conclusion

The PGDprime rapid test for bacteria in platelets can detect bacteria in PD effluent and may be useful for early detection of peritonitis in PD patients. Additional optimization to further adapt the test for PD effluent testing is underway.

Table 1. Detection of Bacteria in PD Effluent by the PGDprime Rapid Test
SpeciesLowest Concentration Detected by PGDprime (CFU/mL)
Klebsiella pneumoniae9.6E+04
Serratia marcescens2.0E+04
Pseudomonas aeruginosa2.7E+04
Escherichia coli1.0E+04
Klebsiella aerogenes2.5E+04
Staphylococcus aureus3.5E+06
Staphylococcus epidermidis2.3E+05
Bacillus cereus1.0E+05

Funding

  • Commercial Support –